摘要:
A navigation system may display a map element represented by a spline including a plurality of vertices. Label coordinate values derived from coordinate values of the plurality of vertices may be retrieved from a database. A label assigned to the map element may be displayed based on the stored label coordinate values. The assigned label may be adapted to the geometric form of at least a portion of the map element.
摘要:
A navigation system may display a map element represented by a spline including a plurality of vertices. Label coordinate values derived from coordinate values of the plurality of vertices may be retrieved from a database. A label assigned to the map element may be displayed based on the stored label coordinate values. The assigned label may be adapted to the geometric form of at least a portion of the map element.
摘要:
In a database usable for a navigation device, object data units comprising information for a three-dimensional displaying of objects like buildings are provided. At least one of the object data units comprises an adjustable height parameter for adjusting a height of the corresponding object when displayed.
摘要:
A vehicle navigation system has a processing device. The processing device receives entries in a first data structure that are generated and are respectively associated with one tile of a tiling. The processing device may compare a three-dimensional terrain on the respective tile with at least one pre-defined tile pattern. Either an identifier for a pre-defined tile pattern or data describing the terrain on the respective tile may be stored by the processing device in the entry.
摘要:
Techniques and mechanisms for programming an accelerator device to enable performance of a data processing algorithm. In an embodiment, an accelerator of a computer platform is programmed based on programming information received from a host processor of the computer platform. In another embodiment, programming of the accelerator is to enable data driven execution of an instruction by a data stream processing engine of the accelerator.
摘要:
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7 or —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
摘要:
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
摘要:
A cleaning arrangement for a lithographic apparatus module may be provided in a collector. The cleaning arrangement includes a hydrogen radical source configured to provide a hydrogen radical containing gas to at least part of the module and a pump configured to pump gas through the module such that a flow speed of the hydrogen radical containing gas provided through at least part of the module is at least 1 m/s. The cleaning arrangement may also include a gas shutter configured to modulate a flow of the hydrogen radical containing gas to at least part of the module, a buffer volume of at least 1 m3 in communication with the module, and a pump configured to provide a gas pressure in the buffer volume between 0.001 mbar (0.1 Pa) and 1 mbar (100 Pa).
摘要:
A lithographic apparatus is configured to project a pattern from a patterning device onto a substrate. The apparatus includes a gas purged sealing aperture extending between at least two different zones of the apparatus, and a gas supplier configured to supply the sealing aperture one or more gases selected from a group including hydrogen, deuterium, heavy hydrogen, deuterated hydrogen, and a mixture of argon and hydrogen.
摘要:
In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.